CJ HealthCare’s ‘Anfrade’ exceeds KRW 20 billon prescriptions in market of its substance

The ‘Anfrade’ series, a CJ HealthCare’s line of chronic peripheral artery disease therapies, first passed KRW 20 billion sales in the market of the same substance.

CJ HealthCare announced on the 18^th that its Anfrade series(Anfrade Tab 100mg, Anfrade SR Tab 300mg) recorded collective KRW 20.3 billion outpatient prescriptions from January to December last year. The Anfrade series is the first p...